InfuSystem (NYSE:INFU) versus Minerva Surgical (NASDAQ:UTRS) Critical Survey

InfuSystem (NYSE:INFU) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares InfuSystem and Minerva Surgical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$134.86 million	0.86	$870,000.00	$0.10	54.75
Minerva Surgical	$51.69 million	0.00	-$34.11 million	N/A	N/A

InfuSystem has higher revenue and earnings than Minerva Surgical.

Profitability

This table compares InfuSystem and Minerva Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Minerva Surgical	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and price targets for InfuSystem and Minerva Surgical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0	0	0	2	4.00
Minerva Surgical	0	0	0	0	0.00

InfuSystem currently has a consensus target price of $13.00, indicating a potential upside of 137.44%. Given InfuSystem’s stronger consensus rating and higher probable upside, research analysts plainly believe InfuSystem is more favorable than Minerva Surgical.

Volatility and Risk

InfuSystem has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Minerva Surgical has a beta of 3.92, suggesting that its share price is 292% more volatile than the S&P 500.

Insider & Institutional Ownership

71.1% of InfuSystem shares are owned by institutional investors. 10.2% of InfuSystem shares are owned by insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

InfuSystem beats Minerva Surgical on 10 of the 11 factors compared between the two stocks.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.